-transparent.png){kind=logo}
Myocarditis, a life threatening disease, is still not adequately treated. Histamine plays an important role in physiology and pathophysiology of cardiovascular system. All four histamine receptors (H1R - H4R), are present in the heart. Experimental autoimmune myocarditis (EAM) was used to investigate which histamine receptor had a greater impact on the disease's progression. EAM was evoked in Lewis rats by porcine myosin immunization. Mepyramine, ranitidine and ciproxifan were used to inhibit H1R, H2R and H3R receptors, respectively, and 2,4-diaminopyrimidines: ST994, ST1012, ST1006 were ligands of H4R. Quinapril, an ACE inhibitor, served as a reference drug. Drugs were administered daily, either from 0 - 2 weeks or from 2 to 4 weeks post EAM induction. Cardiac dysfunction developed with significant decreases in left ventricular ejection fraction and fractional shortening due to dilatation and wall thickening. EAM rats treated with mepyramine and ST994 in weeks 0 - 2 had the lowest decreases. These treated with ST994, ST1012 or quinapril performed much better the following 2 weeks without therapy than did the other groups. On autopsy their hearts were smaller, less fibrotic, histopathological changes in them of a lower grade. When the treatment started with 2 weeks' delay, the ST994-treated EAM rats showed the highest median survival. H4 receptor antagonism inhibits heart remodelling, preserves heart contractility, improves survival and may be of potent therapeutic relevance in human clinics. The blockade of H1 receptor inhibits heart dilatation but does not prolong the life.
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
January 2016,
Bioorganic & medicinal chemistry letters,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
March 2014,
Naunyn-Schmiedeberg's archives of pharmacology,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
September 1993,
Canadian journal of physiology and pharmacology,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
November 2006,
Expert opinion on investigational drugs,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
November 2009,
Molecular pharmacology,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
November 2004,
Mini reviews in medicinal chemistry,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
December 2023,
Naunyn-Schmiedeberg's archives of pharmacology,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
August 2010,
Journal of inflammation (London, England),
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
February 2009,
Expert opinion on therapeutic patents,
A Stasiak, and
J Gola, and
K Kraszewska, and
M Mussur, and
J Kobos, and
U Mazurek, and
H Stark, and
W A Fogel
April 2005,
Inflammation research : official journal of the European Histamine Research Society ... [et al.],
